MTOR and cancer: Nonetheless, compared to transfection with wild-type MTOR, we observed consistent MTORC1 activation when NDD- and cancer-associated MTOR variants were expressed, suggesting that the increase in protein activity due to the pathogenic variants exceeds the feedback inhibition secondary to increased quantity of transfected MTOR, resulting in elevated MTORC1 activity overall.